Helping stroke physicians choose who to thrombolyse - the "Targeting Optimal Thrombolysis Outcomes" (TOTO) study

阿替普酶溶栓是治疗卒中最有效的方法之一，但目前仅用于5%的卒中病例。一个主要的障碍是缺乏工具来确定谁将从治疗中受益，或者谁可能有重大的不良事件。在这项研究中，我们将根据临床数据、先进的CT成像和血液生物标志物制定一项临床决策规则，以帮助确定哪些患者将受益，哪些患者可能出血，以鼓励在急性卒中中更广泛地使用这种治疗方法。

Thrombolysis using alteplase is one of the most effective treatments for stroke but is currently used in only 5% of stroke cases. A major barrier is a lack of tools to identify who will benefit from treatment, or who might have a major adverse event. In this study we will develop a clinical decision rule based on clinical data, advanced CT imaging, and blood biomarkers to help identify those who will benefit and those likely to bleed, to encourage wider use of this treatment in acute stroke.